Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA user fee date for King's Embeda passes without action

This article was originally published in Scrip

Executive Summary

The US FDA's review ofKing Pharmaceuticals' (formerly Alpharma's) Embeda, a modified-released formulation of morphine coupled with the opioid antagonist naltrexone, has been extended beyond the late December user fee date. "Our discussions with the FDA continue to progress, and we remain confident in the strength of our regulatory submission," King chief science officer Eric Carter said. In November an FDA advisory panel said Embeda provided an incremental improvement over existing controlled-release morphine products because it appeared to be less susceptible to abuse and misuse (Scrip Online, November 17th, 2008). However, the panel called for more data on potential abuse through intravenous injection, snorting and chewing, and a risk evaluation and mitigation strategy (REMS) is needed for approval. King gained Embeda through its recent acquisition of Alpharma.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC007677

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel